Screener
Biogen BIIB Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 74%-1.4pp | 75.5%-0.1pp | 75.7%-0.4pp | 75.2%-0.3pp | 75.4%-0.1pp | |
| Net margin | 8.8%-6.5pp | 14.3%-0.8pp | 13.6%-3.3pp | 16%-0.8pp | 15.3%+3.3pp | |
| Returns | ||||||
| Return on equity | 4.8%-4.3pp | 8%-1.2pp | 7.7%-2.7pp | 9.3%-1.2pp | 9.1%+1.5pp | |
| Return on invested capital | 4.6%-3.5pp | 7.8%-0.4pp | 7%-1.4pp | 8.8%-0.3pp | 8%+1.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.9×-0.6× | 3.1×+1.6× | 2.7×+1.3× | 2.7×+1.5× | 2.5×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×+0.1× | 0.4×0.0× | 0.4×+0.1× | 0.4×0.0× | |
| Net debt / EBITDA | 2.9×+1.5× | 1.2×+0.3× | 1.4×-0.2× | 1×-0.2× | 1.4×-0.9× | |
| Per Share | ||||||
| Book value per share | $126.75+5.4% | $125.69+8.5% | $124.11+8.3% | $123.78+10.5% | $120.20+10.4% | |
| Valuation | ||||||
| Market capitalization | $29.99B+54.7% | $26.91B+34.3% | $25.82B+15.9% | $20.54B-27.3% | $18.51B-45.2% | |
| Price / earnings | 33.9×+21.3× | 18.9×+5.4× | 19.2×+5.6× | 12.8×-4.7× | 12.1×-17.0× | |
| Price / sales | 3×+1.1× | 2.7×+0.7× | 2.6×+0.3× | 2×-0.9× | 1.9×-1.6× | |
| Price / book | 1.6×+0.5× | 1.4×+0.3× | 1.4×+0.1× | 1.1×-0.6× | 1×-1.1× | |
| EV / EBITDA | 17×+8.6× | 11.2×+2.8× | 11.4×+1.8× | 8.1×-3.4× | 8.2×-10.3× |
FAQ
- What are Biogen's profit margins?
- Biogen (BIIB) runs a 74.0% gross margin and a 22.9% operating margin, with a 8.8% net margin.
- Where do Biogen's ratios come from?
- Every ratio is computed from Biogen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
